‘High’ hopes for 22nd Century Group
|22nd Century Group Inc is a plant biotechnology company, which provides technology that allows increasing or decreasing the level of nicotine in tobacco plants and cannabinoids in cannabis plants through genetic engineering and plant breeding.
On the 5th of June of this year, the Chairman of 22nd Century Group Inc, (XXII) Nora Sullivan purchased 101,325 shares valued at $83,222 and on the 30th June a further 22,000 shares valued at $17,160. Whilst this is not a huge amount, it does show confidence regarding the future share price for this company going forward.
Other holders include Goldman Sachs Group (154,531 shares) Charles Schwab Investment Management Inc (267,453 shares) BNY Mellon Asset Management (473,625 shares) BlackRock Inc. (2,250,801 shares) ETF Managers Group LLC (13,993,368 shares) Providing we stay above the demand zone it’s our opinion that this is potentially a good stock to hold for the short-medium term and possibly long term.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.